Zepbound

News
Novo Nordisk chief executive Lars Fruergaard Jørgensen

Wegovy slowdown rattles Novo Nordisk investors

Shares in Novo Nordisk have gone into reverse after it reported weaker-than-expected sales of obesity therapy Wegovy, raising concerns among investors about growing competition in the categ